top of page

Media & Press Updates

News: News
SYNG Pharmaceuticals Patent.png

SYNG Pharmaceuticals announces issuance of its Canadian Patent for non-hormonal therapy for endometriosis 

October 06, 2022

SYNG Pharmaceuticals Inc. (SYNG), a Kingston-based women’s health biotech, is pleased to announce that on October 04, 2022, the Canadian Intellectual Property Office granted Canada Patent No. 2,903,608 titled ‘Treatment of endometriosis, angiogenesis and/or endometrial lesion growth’ 


A U.S. patent for this technology was previously granted, bringing the total patent portfolio for SYNG to three granted patents and two pending ones.


“I’m excited by the issuance of this patent which is timely aligned to our increased clinical trial efforts to bring relevant rapid non-invasive diagnostic to market by 2023”, said Vinay Singh, founder and CEO. Singh continued, “We’re looking forward to the strategic partnerships and support from mature biotech or pharma companies to bring this much-needed therapy for women to market sooner.”

Contact us if you would like to schedule a meeting with Vinay Singh, Founder & CEO of SYNG Pharmaceuticals.

SYNG Pharma BIO 2019.png

Meet SYNG Pharmaceuticals at BIO 2019 in Philadelphia

May 15, 2019

SYNG Pharma will be attending BIO International Convention 2019 in Philadelphia, PA June 3-6, 2019

SYNG Pharma will be attending as a member of the Ontario Trade Mission which is also supported by Trade Commissioner Services, Govt. of Canada.


We will be presenting partnership opportunity for our first-in-class Endometriosis Diagnostic. 

Contact us if you would like to schedule a meeting with Vinay Singh, Founder & CEO of SYNG Pharmaceuticals.

seud2019 SYNG Pharma.jpg

SYNG Pharma attends SEUD Congress 2019 as a SEUD Lab finalist.

May 15, 2019

We are pleased to announce that SYNG Pharma is one of the top ten companies selected by a high-profile committee of Society of Endometriosis and Uterine Disorders (SEUD) for its new program, SEUD Lab. SEUD Lab is intended to highlight innovation in women health and providing a platform for knowledge sharing and collaboration amongst emerging companies, researchers and clinicians. 


SYNG Pharma is attending 5th Annual SEUD Conference in Montreal on May 16-17, 2019. 

Contact us if you would like to know more about our simple blood test for endometriosis and non-hormonal therapeutic for endometriosis. 

SYNG Pharma BIO 2018.png

Meet SYNG Pharmaceuticals at BIO 2018 in Boston

May 24, 2018

SYNG Pharma will be attending BIO International Convention 2018 in Boston, MA, June 4-7, 2018

SYNG Pharma is supported by Global Catalyst Program by National Research Council’s Industrial Research Assistance Program (IRAP) in partnership with BIOTECanada and Trade Commissioner Service, Govt. of Canada. 

Contact us if you would like to schedule a meeting with Vinay Singh, Founder & CEO of SYNG Pharmaceuticals.

SYNG Pharma at She loves Tech Canada.jpg

SYNG Pharmaceuticals Presenting at She Loves Tech Canada 2017

August 3, 2017

SYNG Pharma has been selected as one of ten companies to pitch at She Loves Tech Canada 2017. It will be a great chance to meet the wider community of Canadian women in technology and for them to discover SYNG Pharma’s game-changing approach to an area of women’s health which has not received enough attention from industry.

The event will be held at Concordia University’s John Molson School of Business. SYNG Pharma will have a booth and will be pitching to a jury. The winner will win a trip to Beijing to pitch to an international audience and gain world-wide exposure.

About She Loves Canada: She Loves Tech is a global initiative showcasing the convergence of the latest trends in technology, entrepreneurship, innovation and the opportunities it creates for women.


SYNG Pharmaceuticals in Ontario Delegation to BIO 2017 in San Diego

June 23, 2017

SYNG Pharma is one of fifteen companies forming the Ontario trade delegation to BIO International Convention 2017 in San Diego, California, June 19-22, 2017

CEO and founder Vinay Singh held formal meetings with potential investors and partners. SYNG Pharma thanks the Ontario and Canadian governments for their support.

About the BIO International Convention: With over 16,000 attendees, the BIO International Convention is the venue to connect with the world’s top people and technologies in the field of biotech. It is why the Ontario and Canadian federal governments put a lot of effort to bring the top Canadian prospects to this event.


SYNG Pharmaceuticals chose for Innovation Challenge at RESI Toronto 2017

April 4, 2017

SYNG Pharma is one of thirty companies selected for the RESI Innovation Challenge at the RESI (Redefining Early Stage Investments) conference in Toronto

About the RESI Innovation Challenge: Thirty North American companies, selected by Life Science Nation’s scientific and commercial review team, will present directly to investors and potential partners in a poster/exhibition-style format during the RESI conference. Companies will also be competing with each other in a virtual investment contest on the basis of demonstrated innovation and commercial viability. “At the start of the day, each attendee will receive “RESI Cash” to allocate to the entrepreneurs whose technologies they expect will be most influential. The capital invested will be tallied up and the top three winners will receive prizes.”

About RESI: The Redefining Early Stage Investments (RESI) Conference is an ongoing conference series that establishes, “a global circuit for early stage life sciences companies to source investors, create relationships, and eventually, get funding. The RESI conference focuses on a diverse breadth of early stage investors including Family Offices, Venture Philanthropy Funds, VCs, Angel Groups, Corporate Venture Capital Funds, and more.”

SYNG Fertility and Sterility Review .png

Biomarker for Endometriosis Discussed in Recently Published Journal Article

February, 2017

Soo Hyun Ahn, Vinay Singh, and Chandrakant Tayade publish Biomarkers in Endometriosis: Challenges and Opportunities, in the journal Fertility and Sterility. Co-author Singh is the founder of SYNG Pharmaceuticals.

This paper discusses a need for the timely detection of endometriosis. Soo Hyun Ahn and Dr. Chandrakant Tayade, are both of the Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, Ontario, Canada.

SYNG Pharma Biocom 2017.jpg

SYNG Pharmaceuticals chosen to attend Biocom Global Life Science Partnering Conference

February 19, 2017

SYNG Pharmaceuticals was chosen to attend the Biocom Global Life Science Partnering Conference

The Consulate of Canada in San Diego with support from the Ministry of Innovation, Science, and Economic Development and the federal Industrial Research Assistance Program, chose SYNG Pharma as one of ten Canadian companies to receive coaching and mentoring in advance of the 2017 BIOCOM Global Pharma Partnering Conference, March 1-2, 2017. This competition looked for, “drug development biotech firms that have game changing technologies targeting an unmet medical need, with secure IP, eye-popping data, and completed animal studies towards Proof-of-Concept and/or Phase 1 Human Clinical trials.”

SYNG Pharma will receive financial and mentoring support courtesy of the Canadian Trade Commissioner Service in advance of attending the conference. 

Older articles can be accessed through archive.

bottom of page